Cellular Determinants and Function Consequences of PP2A-B56 Degradation by HIV-1 Vif
HIV-1 Vif 降解 PP2A-B56 的细胞决定因素和功能后果
基本信息
- 批准号:10619722
- 负责人:
- 金额:$ 55.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-05 至 2027-04-30
- 项目状态:未结题
- 来源:
- 关键词:APOCEC3G geneAcquired Immunodeficiency SyndromeAddressAffinity ChromatographyBindingBiological AssayCD4 Positive T LymphocytesCRISPR screenCRISPR/Cas technologyCell LineCellsChronicDataDevelopmentDrug TargetingEnvironmentEventFamilyFlow CytometryFluorescenceGene SilencingGenesGenetic ScreeningHIV-1HoloenzymesHumanIndividualInfectionInflammationInflammatoryLabelMalignant NeoplasmsMass Spectrum AnalysisMeasuresMediatingMetabolic DiseasesMolecularMolecular VirologyPathway interactionsPersonsPhosphorylationPhosphorylation SitePlayProcessProtein FamilyProtein SubunitsProtein phosphataseProteinsProteomicsResourcesRetroviridaeRoleSignal TransductionSiteTechnologyTestingTranslationsUbiquitinationViralViral PhysiologyVirionWorkantiretroviral therapybase editingcDNA Expressioncandidate identificationcardiovascular disorder riskcommunity transmissiondrug developmentengineered T cellsfitnessgenome-widemultidisciplinarynovelphosphoproteomicspreventprotein complexprotein degradationreactivation from latencytargeted treatmenttherapy developmentvif Gene Productsvirologyvirus host interaction
项目摘要
PROJECT SUMMARY
The HIV-1 Vif protein is expressed late during infection and has a well-described function to ubiquitinate and
degrade proteins in the APOBEC3 family, thus neutralizing their antiviral activities. More recently, an additional
function of HIV-1 Vif was described by us and others to ubiquitinate and degrade protein phosphatase 2A
holoenzymes containing B56 family regulatory subunits (PP2A-B56). The conservation of Vif-mediated PP2A-
B56 degradation throughout globally circulating HIV-1 subtypes suggests that it is functionally important.
However, there remains a gap in understanding the mechanisms by which PP2A-B56 degradation confers a
fitness advantage to HIV-1. Furthermore, in contrast to APOBEC3 degradation, the host cellular determinants
required for Vif-mediated ubiquitination and degradation of PP2A-B56 are undefined.
In this project, we aim to address these gaps in understanding by defining the cellular determinants and functional
effects of PP2A-B56 degradation by HIV-1 Vif. In Aim 1, we will apply unbiased protein interaction technologies
to determine proteins interacting with PP2A-B56 while it is degraded by Vif. In Aim 2, we will carry out a genome-
wide CRISPR/Cas9 genetic screen to identify genes regulating APOBEC3 and PP2A-B56 degradation. In Aim
3, will test the impact of individual phosphorylation sites regulated by PP2A-B56 in HIV-1 replication in primary
CD4+ T cells. Successful completion of this project will advance understanding of the Vif-PP2A-B56 signaling
axis, potentially leading towards the development of novel classes of antiretroviral therapies that target late
processes of HIV-1 infection.
项目总结
HIV-1 Vif蛋白在感染后期表达,具有众所周知的泛素化和
降解APOBEC3家族中的蛋白质,从而中和其抗病毒活性。最近,又增加了一项
我们和其他人描述了HIV-1 Vif泛素化和降解蛋白磷酸酶2A的功能
含有B56家族调节亚基的全酶(PP2A-B56)。Vif介导的PP2A-的保守性
B56在全球流通的HIV-1亚型中的降解表明它在功能上是重要的。
然而,在理解PP2A-B56降解赋予
对HIV-1的健身优势。此外,与APOBEC3降解相反,宿主细胞决定因素
Vif介导的泛素化和PP2A-B56降解所需的蛋白质尚未定义。
在这个项目中,我们的目标是通过定义细胞决定因素和功能来解决这些理解上的差距
HIV-1 Vif对PP2A-B56降解的影响在目标1中,我们将应用无偏见的蛋白质相互作用技术
目的:确定PP2A-B56被Vif降解时与其相互作用的蛋白质。在目标2中,我们将进行基因组-
广泛的CRISPR/Cas9遗传筛选,以确定调控APOBEC3和PP2A-B56降解的基因。在AIM
3,将测试PP2A-B56调节的单个磷酸化位点在HIV-1初级复制中的影响
CD4+T细胞。该项目的成功完成将促进对Vif-PP2A-B56信号的理解
Axis,可能导致针对晚期的新型抗逆转录病毒疗法的开发
HIV-1感染的过程。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey R Johnson其他文献
Jeffrey R Johnson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey R Johnson', 18)}}的其他基金
Function interactions between mitogen-activated protein kinases (MAPKs) and SARS-CoV-2
丝裂原激活蛋白激酶 (MAPK) 与 SARS-CoV-2 之间的功能相互作用
- 批准号:
10659904 - 财政年份:2023
- 资助金额:
$ 55.14万 - 项目类别:
Characterizing chromatin protein dynamics in HIV-1 latency with a CASPEX approach
使用 CASPEX 方法表征 HIV-1 潜伏期染色质蛋白动态
- 批准号:
10679008 - 财政年份:2022
- 资助金额:
$ 55.14万 - 项目类别:
Characterizing chromatin protein dynamics in HIV-1 latency with a CASPEX approach
使用 CASPEX 方法表征 HIV-1 潜伏期染色质蛋白动态
- 批准号:
10547359 - 财政年份:2022
- 资助金额:
$ 55.14万 - 项目类别:
Multi-dimensional comparison of differentially pathogenic coronaviruses (CoV) in human lung tissue
人肺组织中差异致病性冠状病毒(CoV)的多维度比较
- 批准号:
10495237 - 财政年份:2021
- 资助金额:
$ 55.14万 - 项目类别:
Multi-dimensional comparison of differentially pathogenic coronaviruses (CoV) in human lung tissue
人肺组织中差异致病性冠状病毒(CoV)的多维度比较
- 批准号:
10377826 - 财政年份:2021
- 资助金额:
$ 55.14万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 55.14万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 55.14万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 55.14万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 55.14万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 55.14万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 55.14万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 55.14万 - 项目类别:














{{item.name}}会员




